The White House has amended Executive Order 14195 to increase tariffs on products from the People’s Republic of China (PRC) that are associated with the synthetic opioid supply chain. This decision follows a determination that the PRC has not effectively addressed the influx of synthetic opioids, which pose a significant threat to U.S. national security, foreign policy, and the economy. The tariff increase is part of broader efforts to combat the illicit drug crisis linked to the PRC, reflecting ongoing concerns about the impact of these substances on American communities.

The President’s authority to implement these changes comes from several legislative acts, including the International Emergency Economic Powers Act and the National Emergencies Act. The amendment specifically raises the tariff from 10 percent to 20 percent, underscoring the U.S. government’s commitment to tackling this growing public health crisis. The order also clarifies that it does not create new legal rights or benefits that can be enforced against the United States or its agencies.

In summary, the White House’s action represents a firm stance against the importation of synthetic opioids from China, with the increased tariffs aimed at pressuring the PRC to take more effective measures to combat the drug crisis. The ongoing crisis has not shown signs of abating, prompting the decision for stricter measures. This amendment is part of a larger strategy to protect American citizens from the dangers posed by synthetic opioids.

Original: article